Ombow, Yes, that's the press release I was referring to.
The way it's done in biotech is the company issues a press release ASAP as quickly as they can get the data analyzed. It rarely takes more than a few days or maybe a week for them to get the basic gist of the data and then they must quickly issue a press release with the basic analysis. Then later they sometimes issue a more in depth analysis.
But they don't just sit on the data for week after week like this CEO is doing. I've never seen that before, not to this extent. They legally have to release the results as quickly as possible if the trial results constitute a 'material' event for the company. This is not optional, it's legally required. Companies also want to get the results out quickly to prevent selective leakage which could affect the stock price and result in a class action lawsuit.
The other point I made is that the body of this press release is almost totally about the other non-Covid indications. They are downplaying Covid bigtime, which is what you usually see from a company after a failed trial.
Anyway, good luck, I think you're going to need it. This CEO is bad news.